Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + valproic acid
- Development stage
- Phase 3
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of two medications used for treating seizure disorders. Cannabidiol is a cannabis-derived medication that treats certain types of seizures, while valproic acid is an anticonvulsant that works in brain tissue to stop seizures. When used together, these medications require careful monitoring due to potential interactions, particularly regarding liver function and sedation effects.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADORA1 (Adenosine receptor A1 subtype)CNR1 (Cannabinoid receptor 1)GABRR (GABA-A receptor subunit rho)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on cannabidiol + valproic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + valproic acid.